top of page

Queen Mary University of London and Exactmer Limited KTP 21_22 R3

To develop new synthesis methods for polyethylene glycol polymers, using the Nanostar Sieving platform, a breakthrough technology which will revolutionise polymer fabrication in medicinal applications.

Feedback Overview:

The idea of developing new synthesis methods for polyethylene glycol polymers using the Nanostar Sieving platform is highly innovative and has the potential to significantly impact the pharmaceutical and biotechnology industries. To successfully reach product-market fit, it is crucial to focus on collaboration with pharmaceutical companies for real-world application testing and to secure intellectual property rights for the new technology. Additionally, consider exploring potential partnerships or funding opportunities to accelerate development and commercialization.

Market Competitors:

Market Competitor

Market Competitor

Market Competitor

Market Competitor

Market Competitor

Market Competitor

CTO

Expert in polymer synthesis and advanced fabrication technologies.

What are the potential challenges in scaling up the Nanostar Sieving platform for industrial use?

Scaling up the Nanostar Sieving platform may face challenges such as maintaining consistency in polymer quality, ensuring cost-effectiveness, and meeting regulatory standards for medicinal applications.

How can we ensure the new synthesis methods are compliant with pharmaceutical industry regulations?

Ensuring compliance involves rigorous testing, documentation, and validation of the synthesis methods according to FDA and EMA guidelines, as well as obtaining necessary certifications.

What are the key factors to consider when partnering with pharmaceutical companies for application testing?

Key factors include aligning with the pharmaceutical companies' R&D goals, ensuring clear communication of the technology's benefits, and providing comprehensive data on efficacy and safety.

bottom of page